Healthcare company investor Syncona said its net asset value fell by 7% in the June quarter after it sold investments Blue Earth Diagnostics and Nightstar. The company sold Nightstar to Biogen, with £255.8m of proceeds received in the period, representing a 4.5 times return on original investment. The period also included the sale of Blue Earth Diagnostics to Bracco Imaging, valuing Syncona's holding at £336.9m. 'The sale of Blue Earth ... further enhances Syncona's ability to build and fund its portfolio companies to succeed over the long term,' Syncona said. 'Syncona will continue to fund its companies ambitiously as they scale and sees a strong pipeline of exciting new opportunities, subject to its disciplined approach to the allocation of capital across the portfolio.'
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.